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Objectives
The vast majority of literature on the frequency of the haemorrhagic transformation of ischaemic stroke is based on
imaging studies. The purpose of the present study was to assess the added value of autopsy and neuropathological analy-
sis in a neurology centre with emphasis on acute stroke care.
Methods
We retrospectively analysed the findings of 100 consecutive brain autopsies followed by detailed clinical correlation.
Results
The clinical diagnosis was confirmed by neuropathology in every patient with intracerebral haemorrhage and with
non-cerebrovascular neurological disorders (e.g. primary tumours, metastases, infections). At admission 64 patients (age
62 years, SD 6.5) were diagnosed with acute ischaemic stroke. In 10 of these patients (16%) haemorrhagic transformation
was diagnosed clinically by a second CT. In 24 cases (38%) haemorrhagic transformation was detected only at autopsy.
The distribution of haemorrhagic transformation in our material was the following: small petechiae in 26.5%, more con-
fluent petechiae in 29.4%, ≤ 30% of the infarcted area with some mild space-occupying effect in 29.4% and > 30% of
the infarcted area with significant space-occupying effect or clot remote from infarcted area in 14.7%. Most of the PH1–2
transformations developed in thrombolysed patients and all of the PH2 type transformations were diagnosed already clin-
ically.
Conclusions
We demonstrated that haemorrhagic transformation is frequent and often undiscovered in vivo. Our findings under-
line the importance of post-mortem neuropathological examination also in the era of advanced imaging techniques and
prove that autopsy is the ultimate yardstick of our diagnostic and therapeutic efforts. The high number of haemorrhagic
transformations diagnosed only after death is an important novel finding with clinical implications.
© 2016 Published by Elsevier Ltd.
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1. Introduction
Although the rate of clinical autopsies has been declining dras-
tically for decades, it remains an important tool of quality control
in clinical practice. It serves to determine the exact cause of death,
reveals unexpected complications of disease processes including ad-
verse or any other effects of treatment as well as validates the cause
of death for epidemiological statistics [1–3]. Autopsies make impor-
tant contribution to the under- and postgraduate training in medicine.
Clinico-pathological studies are of major importance, because (agree-
ing with the Agency for Healthcare Research and Quality U.S. Depart-
ment of Health and Human Services) ‘clinical diagnoses, whether ob-
tained from death certificates or hospital discharge data, contain major
inaccuracies compared with autopsy diagnoses’ [4].
⁎ Corresponding author at: Division of Neuropathology, Institute of Pathology, Faculty
of Medicine, University of Debrecen, Nagyerdei krt. 98, H-4032 Debrecen, Hungary.
Email address: hortobagyi@med.unideb.hu, tibor.hortobagyi@kcl.ac.uk (T.
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Our university hospital has a catchment area of 500,000 inhabi-
tants, and about 800 acute stroke patients are treated annually in our
stroke centre. The ratio of thrombolysed patients is 19%, higher than
the average of Western-European countries [5]. In the everyday clini-
cal practice at admission and during the course of the disease the vari-
ous imaging modalities (CT, MRI) provide the main sources of infor-
mation on structural/morphological changes in the brain. Although all
of our acute stroke patients were immediately investigated by CT or
MRI at admission (and repeated if required by the patient's deteriorat-
ing condition), neither ethical nor financial limitations allow perform-
ing daily CT/MRI during the agony phase for estimating the ‘final’
pathological findings of patients with poor outcome. Because the au-
topsy rate of patients who died at our neurology department is > 90%,
we have access to the results of brain autopsies which is a unique op-
portunity in the era of declining brain autopsy rates [3].
Haemorrhagic infarction is a frequent complication of ischaemic
stroke [6–8], although it is not always accompanied by clinical de-
terioration [7–10]. The effect on clinical outcome is also unclear and
most of the literature data regained from studies on thrombolysis for
http://dx.doi.org/10.1016/j.jns.2016.06.055
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ischaemic stroke [7,11,12], mainly due to the fact that haemorrhagic
transformation is a frequent complication of thrombolysis or antico-
agulant therapy. Previous studies have focused on the possible aetio-
logical role of the following parameters: age [8,10,11,13,14], systolic
and diastolic arterial blood pressure [14,15], congestive heart failure
[11], body temperature [15], serum glucose level [8,14], treatment
with anticoagulants [10,15], pre-treatment with aspirin [10,11], early
ischaemic signs on CT [11,13,15], mean infarct volume [10,11,15],
plasma matrix metalloproteinase-9 [15]. The adequate time window
for detection of haemorrhagic transformation is also disputed [16] and
autopsy is the method which provides the most accurate diagnosis
in stroke. Our goals were to i) analyse the correlation between clini-
cal and neuropathological diagnosis; ii) to assess the clinically undis-
closed findings revealed with the neuropathological analysis in a se-
ries of consecutive cases reflecting the routine practice of a stroke cen-
tre, iii) to emphasize the importance of the neuropathological evalua-
tion in establishing the real frequency of haemorrhagic transformation
which may warrant modifications of stroke protocols and diagnosing
clinically undetected brain diseases.
2. Subjects and methods
2.1. Patient population and data collection
We retrospectively analysed the clinical records of patients who
died in the Department of Neurology, University of Debrecen, and
had general autopsy in the Department of Pathology and brain autopsy
in the Neuropathology Laboratory during the previous two calendar
years. All stroke patients were treated on specialized stroke units with
multiparametric monitoring. All patients were older than 18 years of
age, mean age was 62.66 years (SD 6.51). The following data were
collected retrospectively from the patients' clinical notes: sex, age, sur-
vival time after stroke, suspected clinical diagnoses, administration of
antiplatelets and anticoagulants over the hospitalisation, NIHSS (Na-
tional Institutes of Health Stroke Scale) at admission, results of the
performed CT, CTA (computed tomography angiography) or MRI ex-
aminations and the general autopsy findings.
Patients with ischaemic cerebral infarction had acute onset focal
neurological deficit and brain imaging with or without ischaemic le-
sion. Haemorrhagic stroke cases had focal neurological deficit and
brain imaging evidence of intraparenchymal haemorrhage. Cases with
primary intracerebral tumours had histologically verified tumour,
brain imaging evidence of the neoplasm; they were admitted due to
disease progression (deteriorating hemiparesis, dysphagia or epilep-
tic seizures). Patients with brain metastasis had clinically diagnosed
or histologically verified extracerebral primary tumour, brain imag-
ing evidence of the metastasis; they were admitted due to disease pro-
gression (increased intracranial pressure or epileptic seizures) or acute
ischaemic stroke. Patients with central nervous system infection had
evidence of neurological symptoms or meningeal signs indicative of
meningitis or meningo-encephalitis and cerebrospinal fluid analysis
had evidence of elevated cell count and protein content with or with-
out decreased sugar level depending on the infectious agent.
2.2. Neuropathological analysis
Brains were immersed in 10% buffered formalin for 3 weeks ac-
cording to standard procedures [17] to allow good fixation. We mea-
sured the formalin-fixed whole brain and brainstem & cerebellum
weight, respectively, to have the weight ratio of the supra- and in-
fratentorial part as an index of atrophy or weight gain (e.g. due to
oedema). After detailed description of the general appearance coronal
slices of 0.75 cm sickness were cut. This method is adequate to diag-
nose gross pathologies including haemorrhage, infarct, haemorrhagic
transformation and other pathologies such as herniation, secondary
brain stem haemorrhage, arachnoideal cyst, tumours. In cases of
haemorrhagic transformation of cerebral ischaemia we identified the
subtypes according to that Fiorelli et al.: HI1: small petechiae, HI2:
more confluent petechiae, PH1: ≤ 30% of the infarcted area with some
mild space-occupying effect, PH2: > 30% of the infarcted area with
significant space-occupying effect, or clot remote from infarcted area
[7].
After the macroscopic evaluation approximately 2 × 2 × 0.5 cm
tissue blocks were sampled (which fit into standard size cassettes used
for histotechnical processing) from areas recommended by BrainNet
Europe (frontal cortex, temporal cortex, cingulate gyrus, parietal cor-
tex, pre-postcentral gyrus, occipital cortex, hippocampus anterior, hip-
pocampus posterior, basal forebrain, striatum, thalamus, midbrain,
pons, medulla, vermis, cerebellum) [18]. After histotechnical process-
ing and embedding to paraffin wax, sections of 7 μm thickness were
cut and stained with haematoxylin and eosin (H&E), and luxol fast
blue and Nissl (LFB/Nissl) to assess basic pathological changes. Im-
munohistochemistry has also been performed to assess age-related,
neurodegenerative or other pathologies according to standard pro-
cedures [18]; because our study is a clinicopathological analysis of
stroke cases immunohistochemical data were not included in the as-
sessment. Evaluation was performed by a neuropathologist aware of
the sample localization and patient history. The clinical findings were
compared with the neuropathological results.
3. Results
All patients (n = 100) had brain CT at admission. In possible
thrombolysis candidates, computed tomography angiography (CTA)
was also performed at arrival and all thrombolysed patients had a sec-
ond control CT within 24 h after thrombolysis. Repeat CT were done
if the patient's condition deteriorated (loss of consciousness, paresis,
new clinical symptoms, etc.) to exclude any treatable cause of dete-
rioration (e.g. haemorrhage, haemorrhagic transformation, secondary
brainstem haemorrhage, oedema, etc.).
Clinically 64 patients (62.74%, female n = 40, male n = 24, mean
age 62.6 years, SD 6.51) were diagnosed with acute ischaemic stroke
during hospitalisation, regardless of CT signs of ischaemic infarct or
absence of it at admission. In 10 of these patients haemorrhagic trans-
formation of the infarct was diagnosed already by the clinicians (Fig.
1).
At autopsy we found territorial ischaemia in 59 patients (91%) and
lacunar infarct(s) in 5 patients (8%). Brain autopsy revealed haemor-
rhagic transformation in additional 24, altogether in 34 cases (53%)
(16 thrombolysed and 18 non-thrombolysed patients). Data of indi-
vidual patients with haemorrhagic transformation of ischaemic stroke
are listed in Table 1. Among ischaemic stroke cases with haemor-
rhagic transformation there were 21 female and 13 male patients. The
mean age was 75.61 years (SD 9.68). Survival time was 12.03 days
(SD 12.18), which was 15.18 days (SD 15.13) in thrombolysed and
9.22 days (SD 8.27) in non-thrombolysed patients.
All of the acute stroke patients were immediately investigated by
CT at admission (not shown in Table 1). Repeat CT were done in all
thrombolysed patients within 24 h after thrombolysis and in 6 cases
due to clinical worsening. One patient had brain MRI at admission,
due to that hypodensity on his first brain CT was atypical for is-
chaemia. MRI verified acute ischaemia in the territory of middle cere-
bral artery (Table 1).
The distribution of haemorrhagic transformation in our material
was the following: HI1 26.5%, HI2 29.4%, PH1 29.4% and PH2
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Fig. 1. Distribution of cases by major clinical and neuropathological diagnosis (see colour code). The clinical diagnosis was confirmed by neuropathology in every patient with in-
tracerebral haemorrhage and with non-cerebrovascular neurological disorders (primary tumours, metastases, infections). In 10 of these patients haemorrhagic transformation of the
infarct was diagnosed already by the clinicians. Brain autopsy revealed haemorrhagic transformation in 24 additional, all together in 34 cases. *CNS = central nervous system. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
14.7% (Tables 1–2). Fig. 2 shows examples for each subtypes of
haemorrhagic transformation.
None of the patients with haemorrhagic transformation received
oral anticoagulant over their hospitalisation, although 4 of them were
on coumarin or warfarin therapy at admission with ineffective INR
(< 1.7) level. Thirty-one patients received prophylactic low molec-
ular weight heparin (LMWH) therapy and 17 patients received an-
tiplatelet therapy (Table 1). Cases with haemorrhagic transformation
(diagnosed either clinically or by autopsy) consisted of 16 thrombol-
ysed and 18 non-thrombolysed patients (Table 1, Fig. 3). Most of the
PH1 and all of the PH2 type transformations developed in throm-
bolysed patients. All of PH2 transformations were diagnosed already
clinically (Tables 1–2).
According to CT, brain haemorrhage was the clinical diagnosis in
22 patients (21.56%, female n = 6, male n = 16, mean age 75 years,
SD 19.7). The neuropathological findings were confirmatory in all
clinically diagnosed haemorrhagic cases (Fig. 1). According to the
clinical records in one case trauma, in another case anticoagulant
side effect was the aetiological factor. Underlying neuropathology
in the background of cerebral bleeding was revealed in two cases
(cerebral amyloid angiopathy and arteriovenous malformation, respec-
tively). Brain autopsy revealed one clinically unknown cerebral haem-
orrhage; the male patient admitted with symptoms of mild verte-
brobasilar insufficiency died unexpectedly, neuropathological evalua-
tion described severe subarachnoideal haemorrhage as a consequence
of ruptured basilar arterial aneurysm.
Neuropathological evaluation confirmed all primary brain tumours
(n = 3) and metastases (n = 4) cases (Fig. 1). The primary brain tu-
mours were anaplastic astrocytoma in 2 patients and gliosarcoma in
1 patient. The metastases originated from pulmonary adenocarcinoma
(n = 1), invasive ductal breast cancer (n = 1), sigillocellular gastric
cancer (n = 1) and carcinoma of the uvula in the oral cavity (n = 1),
respectively. Infections of the central nervous system (CNS) were
diagnosed clinically in 2 patients. The brain autopsy confirmed the
meningitis in both patients. In four cases with not life-threatening neu-
rological conditions (e.g. neuronal heterotopy and microgyrification;
arachnoideal cyst; silent aneurysm; opalescent meninges with mild
mononuclear infiltration as a late consequence of a previous meningi-
tis) the neuropathological evaluation confirmed the clinical diagnoses.
4. Discussion
The Department of Neurology, University of Debrecen is a re-
gional stroke centre explaining the predominance of stroke patients in
our autopsy series.
Brain autopsy confirmed the clinical diagnoses in all cases of cere-
bral haemorrhages, primer and metastatic tumours and central nervous
system infections (Fig. 1). Neuropathological evaluation revealed the
aetiology in two cases with parenchymal bleeding; it described cere-
bral amyloid angiopathy in one and arteriovenous malformation in
another case. Only brain autopsy could reveal a clinically unknown
cerebral haemorrhage; the male patient was admitted with symptoms
of mild vertebrobasilar insufficiency, while neuropathological eval-
uation described severe subarachnoideal haemorrhage in the back-
ground of unexpected death as a consequence of ruptured basilar arte-
rial aneurysm.
Autopsy provided the most additional information in ischaemic
stroke. There are not many clinico-pathological reports on consec-
utive autopsy series with predominantly stroke cases and only few
with special emphasis on haemorrhagic transformation in ischaemic
infarcts. The reported frequency of HT in previous studies depended
on several factors, e.g. whether the study was based on imaging meth-
ods or on autopsy results, whether the patients had received antico-
agulant, antiplatelet or fibrinolytic treatment, or on the post-stroke
time of control imaging. Additionally, the results of the clinical and
neuropathological diagnostic tools are heterogenous, difficult to com-
pare them, and the population examined can make it even more het-
erogenous due to the fact that autopsy results can be gained from
fatal cases exclusively. Kerényi et al. analysed an autopsy series of
245 patients with ischaemic stroke with haemorrhagic transforma-
tion in 29% [8]. Lodder et al. reported an autopsy series with 48 pa-
tients dying within 15 days following a supratentorial cerebral infarct.
In their analysis 16 patients (33%) had haemorrhagic transformation
[19]. Toni et al. examined 150 consecutive patients with cerebral in-
farct in the anterior circulation. They performed CT or autopsy one
week after the stroke and observed haemorrhagic transformations in
43%, mostly (89%) petechial haemorrhagic transformations and in
11% larger haematomas [6]. Celik et al. evaluated a series of 86 mid-
dle cerebral artery territorial infarction cases, who had received before
neither antiplatelet nor anticoagulant therapy. By the follow up CT
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Table 1
Data of patients with haemorrhagic infarction of ischaemic stroke.
Sexa Age [y] Co-morbidityb Cause of deathc Stroked HTe Survival timef Control CTg NIHSS 0 hh rtPA/TAG/anticoagulanti
F 71 HT, DM, PF, Mj BP AB HI-1cl. 60 days 24 h 18 ia./−/LMWH
M 74 HT, MI, S, COPD AMI ICA HI-2 path. 26 days 5 days 12 −/+/LMWH
F 77 HT, DM, PF, MI, COPD H AB PH-1cl. 2 days 24 h ia./−/−
M 63 HT EP AB PH-1cl. 25 days 24 h 11 iv./+/LMWH
M 63 HT, DM, PF, COPD, PAD BP MCA PH-2cl. 6 days 1.5 h, 24 h, 48 h 14 iv./−/coumarin*
F 74 HT, MI, COPD BP MCA HI-1 path. 35 days 24 h 13 iv./+/LMWH
M 78 HT, PF, MI, S BP MCA PH-1 path. 11 days 24 h 21 iv./+/LMWH
M 70 HT, S, PAD BP MCA HI-1 path. 14 days MRI at admission 16 −/+/LMWH
F 63 HT, DM, PAD BP MCA HI-1 path. 7 days 14 −/+/LMWH
F 86 HT, S BP MCA HI-1 path. 20 days 14 −/+/LMWH
F 73 HT, COPD BP MCA HI-1 path. 9 days 4 h 13 −/+/LMWH
F 77 HT, PF, MI, S BP ICA HI-path. 5 days 13 −/−/coumarin*, LMWH
F 70 HT, DM, S BP MCA HI-2 path. 29 days 16 −/+/LMWH
F 92 PF, MI, S BP ICA HI-2 path. 3 days 6 h 21 −/+/−
M 73 HT BP MCA PH-1 path. 8 days 14 −/+/LMWH
F 71 HT, DM, MI BP ICA PH-1 path. 4 days 6 −/+/LMWH
M 67 HT, M SH MCA HI-2cl. 11 days 24 h iv./+/LMWH
M 76 HT, PF SH MCA PH-2cl. 7 days 24 h, 2 days 8 iv./+/−
M 68 HT SH ICA PH-1 path. 18 days 24 h, 4 days 23 iv./+/LMWH
F 79 HT, DM, PF, COPD CF AB, AV PH-1cl. 8 days 24 h 13 iv./−/LMWH
F 69 HT, DM, PF, MI, S CF MCA PH-2cl. 3 days 24 h 21 iv./−/warfarin*
F 84 HT, COPD CF MCA PH-2cl. 6 days 24 h 24 iv./−/−
M 83 PF CF MCA HI-1 path. 10 days 24 h 21 iv./+/LMWH
F 78 HT, DM CF MCA HI-2 path. 26 days 24 h, 13 days 5 iv./+/LMWH
M 70 HT CF MCA PH-1 path. 4 days 24 h 16 iv. + ia./+/−
F 89 HT, DM, PF CF MCA HI-1 path. 5 days 3 days 19 −/+/coumarin*, LMWH
F 92 HT, S, COPD CF MCA HI-2 path. 14 days −/+/LMWH
M 89 HT, DM, PF CF MCA HI-2 path. 33 h 11 −/+/LMWH
F 99 HT, S, COPD CF MCA HI-2 path. 5 days 17 −/+/LMWH
F 83 HT, DM, PF, M CF MCA HI-2 path. 6 days 24 −/+/LMWH
F 56 HT, PAD, S, COPD CF MCA PH-1 path. 27 h 20 −/+/−
F 66 HT, DM, MB CF AV PH-1 path. 2 days −/+/−
M 69 HT, DM, MI PE MCA PH-2cl. 11 days 24 h, 10 days 19 iv./+/LMWH
F 79 HT PE MCA HI-2 path. 7 days 19 −/+/LMWH
a Sex: F = female, M = male.
b Co-morbidities: HT = hypertonia, DM = diabetes mellitus, PF = atrial fibrillation, S = stroke in patient's history, M = malignancy in patient's history, COPD = chronic obstructive
pulmonary disease, PAD = peripheral arteriosclerosis, MI = myocardial infarct in patient's history, MB = artificial valv in the heart.
c Cause of death: BP = bronchopneumonia, H = herniation, PE = pulmonary embolia, CF = cardiac failure, SH = secundary haemorrhage in the brain stem, AMI = acute myocardial
infarct.
d Localization of stroke: ICA = internal carotid artery, MCA = middle cerebral artery, AB = basilar artery, AV = vertebral artery.
e Type of haemorrhagic transformation (HT): HI1 = small petechiae, HI2 = more confluent petechiae, PH1 = ≤ 30% of the infarcted area with some mild space-occupying effect,
PH2 ≥ 30% of the infarcted area with significant space-occupying effect or clot remote from infarcted area, cl = already clinically diagnosed haemorrhagic transformation (which
was confirmed by neuropathological evaluation, too), path = haemorrhagic transformation diagnosed only by neuropathological examination.
f Survival time: time between stroke and death.
g Control CT: time of control CT calculated from the time of admission. Repeat CT were done in all thrombolysed patients within 24 h after thrombolysis and in all cases when
clinicians detected deterioration of the patient's neurological status.
h NIHSS 0 h: NIHSS at admission.
i rt-PA/TAG/anticoagulant: rt-PA = recombinant tissue plasminogen activator (Alteplase), iv = intravenous thrombolysis, ia = intraarterial thrombolysis, iv + ia = combination of
intravenous and intraarterial thrombolysis, TAG: antiplatelet medication (acetylsalicylic acid or clopidogrel), LMWH = low molecular weight heparin.
j Four of the patients with haemorrhagic transformation were on coumarin or warfarin therapy at admission with ineffective INR (< 1.7) level. After the diagnosis of stroke none of
the patients received vitamin K antagonist.
performed 72 h after stroke they found HT in 8.5% of all examined
patients, but in 40.6% of middle cerebral artery territorial infarction
cases [14]. Okada et al. examined 160 acute ischaemic stroke pa-
tients. Their CT based results showed all together 40.6% HT, from
which 15.4% could be seen in the first 1–4 days, 67.7% in the first
10 days and 100% within the first 30 days and they haven't detected
any new HTs after the first month [20]. Hornig et al. evaluated 65
patients' data. They detected HT with brain CT in 28 cases, 40% in
the first week, and the rest 60% in the second post-stroke week [16].
These earlier reports show how difficult it is to define the most ap-
propriate time for the diagnosis of HT. Furthermore, diagnostic pos-
sibilities are often different in the routine practice as compared to
well-defined and sponsored studies which last for a particular period
of time. Moreover, ischaemic stroke patients usually have days or
weeks [8,19] (in our sample 11.71 days, SD 13.16) before death with
reduced level of consciousness and critical medical status. Therefore,
the premortal diagnosis of haemorrhagic transformations could only
be possible with daily repeat CT or MRI during the critically ill pe-
riod, which is not possible either from the ethical or the financial point
of view. Repeat CT are done in all thrombolysed patients within 24 h
after thrombolysis [21], but not necessarily performed in non-throm-
bolysed patients, if the patient's condition doesn’t requires or allows it.
However it is well established that HT is not necessarily accompanied
by deterioration of neurological status [7–10]. Fiorelli et al. reported
that only parenchymal haematoma type 2 was associated with an in-
creased risk of clinical worsening (at 24 h after stroke onset) and of
death (at 3 months); all other types of haematomas did not indepen-
dently increase the risk of late deterioration [7].
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Table 2
Distribution of morphological types of haemorrhagic transformation in clinically or
neuropathologically diagnosed patients.
Non-thrombolysised Thrombolysised
Clinically
diagnosed
Neuropathologically
diagnosed
Clinically
diagnosed
Neuropathologically
diagnosed
HI1 0 6 1 2
HI2 0 8 1 1
PH1 0 4 3 3
PH2 0 0 5 0
All 0 18 10 6
HI1: small petechiae, HI2: more confluent petechiae, PH1: ≤ 30% of the infarcted
area with some mild space-occupying effect, PH2: > 30% of the infarcted area with
significant space-occupying effect or clot remote from infarcted area.
The clinically diagnosed columns include those cases where the haemorrhagic
transformation was detected by the control brain CT in vivo. The neuropathologically
diagnosed columns include only those cases where clinically the haemorrhagic
transformation was unknown and only the neuropathological evaluation detected it.
The reported frequency of the different types of HT in the literature
depends on the treatment used in the acute phase of ischaemic stroke,
but also on the HT subtypes' definitions used in that particular study.
The distribution of haemorrhagic transformation in our material was
the following: HI1 26.5%, HI2 29.4%, PH1 29.4% and PH2 14.7%
(Table 2). Okada et al. defined four types of HT: spotty and scattered
petechial haemorrhage, along the cortical margin of the ischaemic le-
sion (56.9%), diffuse haemorrhage (18.5%), small (< 3 cm in diam-
eter) (13.8%) and massive (> 3 cm in diameter) (10.8%) haematoma
[20]. Fiorelli et al. examined the subtypes and frequency of HT after
iv. rtPA treatment in the ECASS I [7]. HT detection was based on con-
trol brain CT performed 36 h later. Due to the very different patient
population from ours and the exclusively imaging-based HT diagno-
sis, the comparison between their and our results is meaningless. How-
ever, their results support those previous findings that the frequency
and even the severity of HT are higher after rtPA treatment [10,11,22].
In our sample most of the PH1–2 transformations developed in throm-
bolysed patients (Table 2, Fig. 3). The high proportion of HT in our
sample diagnosed only at brain autopsy can be explained partially by
the fact that control CT is performed only 24 h after thrombolysis [21].
Although the half-life of t-PA is only few minutes, there is a prolonged
effect on the coagulation cascade [23,24].
Fiorelli et al. [7] and Berger et al. [22] evaluated the ECASS I and
ECASS II data and established that only parenchymal haematoma type
2 was associated with an increased risk of clinical deterioration; all
other types of haematomas did not independently increase the risk of
late deterioration. In the NINDS rtPA study [25] 70% of the symp-
tomatic HT corresponded to the parenchymal haematoma (PH1 and
PH2) subtypes by ECASS classification [26–28]. The vast majority
(73.5%) of symptomatic HT in the ECASS were in the PH1 and PH2
subgroups [11]. These data show that HTs accompanied by clinical
worsening usually belong to parenchymal haemorrhages, appear as
dens haematomas and they have pronounced space occupying effect.
In our sample PH2 type transformations developed in thrombolysed
patients and all of them were diagnosed already clinically. On the
other hand, relatively large proportion of HT1–2 and PH1 haemor-
rhagic transformations were diagnosed only by brain autopsy even in
a specialized stroke unit with multiparametric monitoring, despite the
control CTs 24 h later in thrombolysed patients and other control CTs
performed due to clinical worsening (in 6 cases).
Although some prior studies demonstrated the negative impact
of the asymptomatic haemorrhagic transformations, even of the HI
forms, on the outcome compared with those without HT of acute is-
chaemic stroke [29,30]. According to a previous study, based on both
imaging and autopsy results, the pathogenesis of haemorrhagic in-
farctions and parenchymal haematomas are different; while haemor-
rhagic infarctions are the consequences of multifocal extravasation of
red blood cells, usually in the grey matter, parenchymal haematomas
probably represent haemorrhages from single damaged vessels, in-
jured by ischaemia and following reperfusion [31]. Since the transfor-
mation occurs in the already necrotic tissue, often no clinical wors-
ening, reflecting the development of HT, could be detected [32].
The general clinical condition of acute stroke patients with fatal out-
come is very poor, there are several additional extracerebral factors
(i.e. bronchopneumonia, acute myocardial infarction, pulmonary em-
bolism) which may lead to the fatal outcome.
Instead of focusing on the reasons, clinical signs or treatment of
haemorrhagic transformations, our aim was to emphasize the higher
than expected frequency of its occurrence even without clinical signs
and emphasize the need of clinical alertness even in asymptomatic
cases. Since we evaluated only fatal cases, our results cannot be ex-
trapolated to all ischaemic stroke cases. However keeping this in
mind, in individual cases (e.g. in thrombolysed patients) clinicians
may consider requesting brain CT short before discharging the is-
chaemic stroke patient.
Additionally we underline the importance of clinical autopsies
which are still crucial in the correct diagnosis of haemorrhagic trans-
formation of fatal stroke cases even in the era of advanced imaging
techniques. Our study provided solid evidence that post-mortem neu-
ropathological examination is important not only in confirming the
clinical diagnosis but also reveals in a high proportion of patients
undisclosed clinically relevant brain pathologies. Furthermore, post-
mortem neuropathology is of educational value for trainees and spe-
cialists alike in clinical neurosciences, imaging and general pathology.
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Fig. 2. Examples for different types of haemorrhagic transformation. a) HI1: small petechiae (arrow) b) HI2: more confluent petechiae (arrow) c) PH1: ≤ 30% of the infarcted area
with some mild space-occupying effect (arrow) d) PH2: > 30% of the infarcted area with significant space-occupying effect (arrow) e) PH2: clot remote from infarcted area (arrow-
head).
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Fig. 3. Occurrence of haemorrhagic transformation evaluated by brain autopsy in thrombolysed and non-thrombolysed patients with ischaemic stroke (see colour code). All the cases
in the figure are diagnosed by brain autopsy (including also those 10 cases diagnosed already clinically, too). Clinically 64 patients were diagnosed with acute ischaemic stroke during
hospitalisation, in 34 of these patients haemorrhagic transformation of the infarct was diagnosed or confirmed by brain autopsy. Cases with haemorrhagic transformation consisted of
16 thrombolysed and 18 non-thrombolysed patients. Most of the PH1 and all of the PH2 type transformations developed in thrombolysed patients. (For interpretation of the references
to colour in this figure legend, the reader is referred to the web version of this article.)
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